Cargando…

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

Tumour-inhibitory effects of a new antagonist of growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 and in Copenhagen rats implanted with Dunning R-3327 AT-1 prostatic adenocarcinoma. After 6 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jungwirth, A., Schally, A. V., Pinski, J., Halmos, G., Groot, K., Armatis, P., Vadillo-Buenfil, M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223520/ https://www.ncbi.nlm.nih.gov/pubmed/9184172

Ejemplares similares

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
por: Szepeshazi, K, et al.
Publicado: (2000)

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
por: Perez, Roberto, et al.
Publicado: (2012)

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
por: Pinski, J., et al.
Publicado: (1994)

Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs
por: Akhter, Mohammad S., et al.
Publicado: (2020)

Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines
por: Barabutis, N, et al.
Publicado: (2008)

Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin
por: Zhang, Chongxu, et al.
Publicado: (2019)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway
por: Guo, Jian, et al.
Publicado: (2010)

SAT-603 Growth Hormone-Releasing Hormone (GHRH) Antagonists Stimulate Feeding in Mice
por: Leone, Sheila, et al.
Publicado: (2020)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches
por: Szabo, Zsuzsanna, et al.
Publicado: (2022)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone–Releasing Hormone Peptide Analogues
por: Jeanne Dit Fouque, Kevin, et al.
Publicado: (2018)

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
por: Villanova, Tania, et al.
Publicado: (2019)

Growth hormone releasing hormone induces the expression of nitric oxide synthase
por: Barabutis, Nektarios, et al.
Publicado: (2011)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Activity of the growth hormone‐releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis‐like granuloma
por: Zhang, Chongxu, et al.
Publicado: (2021)

Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)
por: Muñoz‐Moreno, Laura, et al.
Publicado: (2022)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
por: Rajaram, Pravien, et al.
Publicado: (2020)

Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression
por: Wu, Hsien-Ming, et al.
Publicado: (2016)

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK
por: Rosario, Derek J., et al.
Publicado: (2016)

Hormones and prostate carcinogenesis: Androgens and estrogens
por: Bosland, Maarten C., et al.
Publicado: (2011)

Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study
por: Perez, Roberto, et al.
Publicado: (2014)

Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
por: Zhang, Chongxu, et al.
Publicado: (2020)

Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1
por: Cui, Tengjiao, et al.
Publicado: (2018)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
por: Kunath, Frank, et al.
Publicado: (2015)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists
por: Chatzistamou, I, et al.
Publicado: (2000)

P-Glycoprotein and Androgen Receptor Expression Reveals Independence of Canine Prostate Cancer from Androgen Hormone Stimulation
por: Cavalca, Alexandre Matheus Baesso, et al.
Publicado: (2022)

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines
por: Sipos, Eva, et al.
Publicado: (2018)

Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling
por: Gesmundo, Iacopo, et al.
Publicado: (2021)

Gonadotrophin releasing hormone antagonist in IVF/ICSI
por: MS, Kamath, et al.
Publicado: (2008)

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels
por: Okamoto, Kohei, et al.
Publicado: (2015)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
por: Liu, Yi-Fu, et al.
Publicado: (2021)

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.
por: Bokser, L., et al.
Publicado: (1990)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
por: Kashiwabara, Takeshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0be106cskkv0r21gfldc3mcm2n